(CercleFinance.com) – GenSight Biologics rose more than 2% on Monday on the Paris Stock Exchange following the publication of encouraging follow-up data concerning its Lumevoq gene therapy.
According to the biopharmaceutical company, subjects with Leber’s hereditary optic neuropathy (LHON) treated with the product continued to experience marked improvement in their vision for four years, even after a single injection.
According to GenSight, these data validate and extend the observations to three years, confirming that the improvement in visual acuity is sustained and associated with improved quality of life, without any long-term safety concerns.
These results come from the phase III clinical trial ‘Restore’, one of the largest long-term follow-up studies for the treatment of a rare disease, with 62 subjects recruited.
As a reminder, the examination of the marketing authorization application for Lumevoq is in progress in Europe, with a decision from the CHMP expected in the fourth quarter.